Adverse skeletal related events in patients with bone-metastatic pheochromocytoma/paraganglioma-Reference-Cited by-同舟云学术

Adverse skeletal related events in patients with bone-metastatic pheochromocytoma/paraganglioma

Published:2024-09 Issue: Volume:208 Page:114122
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Laganà Marta,Habra Mouhammed Amir,Remde Hanna,Almeida Madson Q.,Cosentini Deborah,Pusceddu Sara,Grana Chiara Maria,Corssmit Eleonora P.M.,Bongiovanni Alberto,De Filpo Giuseppina,Lim Eugenie S.,Zamparini Manuel,Grisanti Salvatore,Deutschbein Timo,Fassnacht Martin,Fagundes Gustavo F.C.,Pereira Maria Adelaide A.,Oldani Simone,Rota Simone,Prinzi Natalie,Jimenez Camilo,Berruti Alfredo

Publisher

Elsevier BV

Reference16 articles.

1. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up;Fassnacht;Ann Oncol,2020

2. Moog, S., Lussey-Lepoutre C., & Favier J. Epigenetic and metabolic reprogramming of SDH-deficient paragangliomas. Endocr Relat Cancer. 27(12), R451-R463. https://doi.org/10.1530/ERC-20–0346.

3. Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma;Ayala-Ramirez;J Clin Endocrinol Metab,2013

4. New directions in treatment of metastatic or advanced pheochromocytomas and sympathetic paragangliomas: an American, contemporary, pragmatic approach;Jimenez;Curr Oncol Rep,2022

5. E. Baudin, B. Goichot, A. Berruti, et al. Annals of Oncology (2021) 32 (suppl_5): S621-S625. 10.1016/annonc/annonc700. 567O_PR - First International Randomized Study in Malignant Progressive Pheochromocytoma and Paragangliomas (FIRSTMAPPP): An academic double-blind trial investigating sunitinib.